EUVIMEDEUVIMED entdecken
Crossref

Quantifying HLA Mismatches at Epitope Level in Haplo‐ HSCT : Impact in the Outcome in Strategies Using PTCy

Francisco Javier Gil-Etayo iD, Jairo Eduardo Niño-Ramírez iD, Marta Fonseca-Santos, Daniel Arroyo-Sánchez iD, Almudena Navarro-Bailón, Ariadna Vicente Parra iD, Isabel Jiménez Hernaz iD, Pilar Terradillos Sánchez iD, Francisco Boix iD, Miguel Alcoceba iD, Luis Marín, Estefanía Pérez-López und 12 weitere

HLA · 2024

DOI: 10.1111/tan.15738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HLA, 2024. Verfasst von Francisco Javier Gil-Etayo und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University Hospital of Salamanca, Salamanca, Spain. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, HLA Antigens, Epitopes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Haploidentical haematopoietic stem cell transplantation (haplo‐HSCT) is one of the most effective therapies for treating malignant haematological disorders. However, HLA disparities are significant barriers to the success of this process since they increase the risk of graft versus host disease (GvHD). HLA disparities quantification could help to anticipate the probability and degree of GvHD, but the best tool for such quantification remains a challenge. The aim of this study was to quantify the degree of HLA epitope incompatibilities using PIRCHE (Predicted Indirectly Recognisable HLA Epitopes) algorithm for immunogenicity prediction and their potential relationship with GvHD degree and clinical outcome. We studied 145 patients who underwent a haplo‐HSCT with post‐transplant cyclophosphamide (PTCy) from a related donor between 2013 and 2020 at our centre evaluating molecular HLA mismatches by PIRCHE‐algorithm. Patients with PIRCHE Score (PS) I + II > 38 in GvH direction, developed acute GvHD grade II–IV earlier than their counterparts (HR: 1.71, 95% CI: 1.02–2.87, p = 0.032). In addition, PS‐B > 1 in GvH direction was an independent risk factor for chronic GvHD, (HR: 2.51, 95% CI 1.17–5.36, p = 0.017). A higher incidence of relapse was found for patients with PS‐II > 28 HvG (HR: 9.16, 95% CI: 2.47–33.92, p < 0.001) which also favoured a worse GvHD/relapse‐free survival in patients with PS‐II > 27 in HvG direction (HR: 1.88, 95% CI: 1.11–3.18, p = 0.017). These findings indicate that the alloreactivity inferred by epitope HLA disparities is associated with post‐transplant outcomes. Thus, analysing PS could benefit the selection of the most suitable donors allowing patient stratification based on HLA mismatches in the context of haplo‐HSCT with PTCy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseaseHLA AntigensEpitopesCyclophosphamideHistocompatibility TestingHumansFemaleMaleAdultMiddle AgedTransplantation, HaploidenticalAlgorithmsAdolescentYoung AdultHematologic NeoplasmsAgedImmunosuppressive Agents

Stichwörter der Autor:innen

GRFSGvHDHLAPIRCHEepitopehaplo‐HSCT

Substanzen

HLA AntigensEpitopesCyclophosphamideImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
  • Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
  • Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
  • Centro de Investigación Contra el Cáncer (CIC), Salamanca, Spain.
  • Transfusion Centre of Comunidad Valenciana, Valencia, Spain.
  • Immunology Unit, Clinical Analysis Department, Albacete University Hospital Complex, Albacete, Spain.

ORCID-Profile: Francisco Javier Gil-Etayo, Jairo Eduardo Niño-Ramírez, Daniel Arroyo-Sánchez, Ariadna Vicente Parra, Isabel Jiménez Hernaz, Pilar Terradillos Sánchez, Francisco Boix, Miguel Alcoceba, Fermín Sánchez-Guijo, Ramón García-Sanz, Lucía López-Corral, Amalia Tejeda Velarde

Zitieren

APA

Gil-Etayo, F. J., Niño-Ramírez, J. E., Fonseca-Santos, M., Arroyo-Sánchez, D., Navarro-Bailón, A., Vicente Parra, A., Jiménez Hernaz, I., Terradillos Sánchez, P., Boix, F., Alcoceba, M., Marín, L., Pérez-López, E., Cabrero, M., Martín-López, A. Á., López, M., Baile, M., Avendaño, A., Cabero, A., García-Bacelar, A., …, & Tejeda Velarde, A. (2024). Quantifying HLA Mismatches at Epitope Level in Haplo‐ HSCT : Impact in the Outcome in Strategies Using PTCy. HLA. https://doi.org/10.1111/tan.15738

Vancouver

Gil-Etayo FJ, Niño-Ramírez JE, Fonseca-Santos M, Arroyo-Sánchez D, Navarro-Bailón A, Vicente Parra A, et al. Quantifying HLA Mismatches at Epitope Level in Haplo‐ HSCT : Impact in the Outcome in Strategies Using PTCy. HLA. 2024. doi:10.1111/tan.15738

BibTeX
@article{GilEtayo2024,
  author = {Gil-Etayo, Francisco Javier and Niño-Ramírez, Jairo Eduardo and Fonseca-Santos, Marta and Arroyo-Sánchez, Daniel and Navarro-Bailón, Almudena and Vicente Parra, Ariadna and Jiménez Hernaz, Isabel and Terradillos Sánchez, Pilar and Boix, Francisco and Alcoceba, Miguel and Marín, Luis and Pérez-López, Estefanía and Cabrero, Mónica and Martín-López, Ana África and López, Miriam and Baile, Mónica and Avendaño, Alejandro and Cabero, Almudena and García-Bacelar, Ana and Vázquez, Lourdes and Sánchez-Guijo, Fermín and García-Sanz, Ramón and López-Corral, Lucía and Tejeda Velarde, Amalia},
  title = {Quantifying HLA Mismatches at Epitope Level in Haplo‐ HSCT : Impact in the Outcome in Strategies Using PTCy},
  journal = {HLA},
  year = {2024},
  doi = {10.1111/tan.15738}
}
Kostenlos starten →